Every 8-K that Bluejay Diagnostics, Inc. (BJDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BJDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BJDX filings page.
Bluejay Diagnostics, Inc. (BJDX) entered into a Distribution, Co-Marketing & Strategic Partnership Agreement with Lovell Government Services, Inc., a Service-Disabled Veteran-Owned Small Business, to distribute Bluejay’s medical diagnostic products to U.S. federal, state and local government customers following applicable FDA clearance or other required regulatory authorization.
Lovell receives a non-exclusive right to list and resell Bluejay’s products in open-market government procurements and a sole and exclusive right for federal procurement opportunities requiring or favoring SDVOSB set-aside status, including VA, DoD and IHS channels via vehicles such as VA Federal Supply Schedule, GSA Advantage, MAS, ECAT and DAPA. Bluejay paid a one-time $5,500 establishment fee; Lovell earns an approximate 15% distribution fee on gross sales through its federal catalogs and an additional 2% fee on sales via DAPA prime vendors, with these fees added to Bluejay’s cost of goods sold rather than reducing its profit margin.
The agreement runs for an initial two-year term with automatic one-year renewals unless either party gives 90 days’ notice of non-renewal. Lovell must remit payment within three business days after receiving funds from the government customer or within 30 days of a valid invoice, whichever is later; unpaid undisputed amounts accrue interest at up to 18% per annum. Either party may terminate immediately for specified adverse events, such as certain sanctions, bankruptcy, or a final judgment over $100,000, or for uncured defaults after 30 days’ notice. A co-marketing framework supports joint outreach to federal healthcare stakeholders as Bluejay advances toward potential commercialization.
Bluejay Diagnostics, Inc. reported an update for the quarter ended June 30, 2026, highlighting progress on its Symphony™ platform and lead Symphony IL-6 test while strengthening its balance sheet. The company completed targeted enrollment of 750 hospital patients in the SYMON-II pivotal clinical validation study and is advancing analytical and clinical validation work intended to support a future FDA 510(k) submission.
At June 30, 2026, Bluejay held approximately $9.6 million in cash and cash equivalents, up from approximately $5.2 million at December 31, 2025. During the first half of 2026, it generated about $7.7 million of net cash from financing activities, including roughly $7.6 million of net proceeds from a June 2026 private placement. Management estimates current cash resources will fund operations through the second quarter of 2027, with capital allocation focused on manufacturing readiness, regulatory submission activities, and commercialization planning for Symphony. The Symphony platform remains an investigational device and will require U.S. Food and Drug Administration authorization before it can be marketed as a diagnostic product in the United States.
Bluejay Diagnostics, Inc. reports successful completion of patient enrollment in its SYMON-II multicenter clinical validation study, reaching its target of 750 sepsis patients ahead of plan. SYMON-II is a pivotal study evaluating the Symphony IL-6 test for early assessment of 28-day all-cause mortality risk in ICU sepsis patients.
Preliminary observations show an approximately 17% 28-day mortality rate in the enrolled population, providing a large dataset to assess the prognostic utility of IL-6. The company states that SYMON-II is intended to validate earlier findings and is part of a clinical program it plans to use to support a future FDA 510(k) application and potential commercialization of its investigational Symphony rapid, near-patient diagnostic platform.
Bluejay Diagnostics, Inc. held its 2026 annual stockholder meeting and approved several key proposals. Stockholders adopted an amendment to the 2021 Stock Plan, increasing the shares reserved for equity awards by 600,000, bringing the total plan reserve to 600,061 shares.
They also approved an amendment to the certificate of incorporation authorizing a potential reverse stock split at a ratio between 1-for-2 and 1-for-20, to be implemented at the board’s discretion no later than June 9, 2027. The board currently has no intention to implement the split and the stock was trading at $4.50 per share, in compliance with Nasdaq’s $1.00 minimum bid requirement.
All five incumbent directors were re-elected, and Wolf & Company, P.C. was ratified as independent auditor for the year ending December 31, 2026. At the record date, there were 1,034,715 shares outstanding, with 414,092 shares represented at the meeting, constituting a quorum.
Bluejay Diagnostics, Inc. completed a private placement of common stock and warrants generating gross proceeds of $8.5 million and approximately $7.7 million in net proceeds. Investors purchased 3,655,917 shares of common stock (or pre-funded warrants) plus Series G and Series H warrants to buy up to 3,655,917 shares each.
The securities were priced at $2.325 per share (or pre-funded warrant) with accompanying warrants, and the Series G and H warrants carry an exercise price of $2.075 per share. Bluejay plans to use the funds for FDA approval efforts, related clinical studies, other research and development, and general working capital.
Bluejay Diagnostics, Inc. entered a material definitive agreement with Argonaut Manufacturing Services to provide U.S.-based manufacturing and related services for Bluejay’s Symphony™ platform IL-6 testing products. Argonaut will support planning, engineering, sourcing, supply chain management, formulation, filling, finishing, quality control testing, capital equipment procurement, storage, delivery, and distribution under purchase orders issued over time.
The partnership is intended to establish scalable domestic manufacturing, reduce reliance on overseas production, and strengthen Bluejay’s future commercial infrastructure, including broader U.S. product distribution and greater supply chain resilience. The collaboration supports Bluejay’s ongoing clinical development programs and future commercialization plans for its near-patient diagnostic solutions.
Bluejay Diagnostics, Inc. provided a first quarter 2026 corporate and financial update focused on its Symphony near-patient diagnostic platform for sepsis care. The company highlighted ongoing clinical, manufacturing, and regulatory work to advance its investigational Symphony IL-6 test, including continued enrollment momentum in the pivotal SYMON-II study.
As of March 31, 2026, Bluejay reported cash and cash equivalents of approximately $3.7 million. Net loss was approximately $1.9 million for the first quarter of 2026, roughly in line with the same period in 2025. Symphony and the IL-6 Test remain investigational and not yet cleared by the U.S. Food and Drug Administration.
Bluejay Diagnostics, Inc. provides an update on patient enrollment in its pivotal SYMON-II clinical trial of the Symphony IL-6 test for sepsis triage and monitoring. The company has successfully enrolled 624 patients toward a target of 750 and expects to complete enrollment in the next 2 to 3 months, depending on site activity and patient flow.
The trial is designed to clinically validate Bluejay’s Symphony IL-6 test, which aims to deliver rapid, near-patient results in critical care settings to help clinicians assess patient severity and guide timely treatment decisions. SYMON-II is part of a broader SYMON clinical program that the company plans to use to support a 510(k) submission to the FDA for its investigational Symphony System.
Bluejay Diagnostics, Inc. entered into a securities purchase agreement with its senior leaders and directors for a small insider-funded capital raise. The company issued 62,500 shares of common stock in a private placement at $2.00 per share, generating gross proceeds of $125,000.
The purchasers were President and CEO Neil Dey, Board Chair Donald Chase, and directors Svetlana Dey, Douglas Wurth and Fred Zeidman, each acquiring 12,500 shares for their own account. The shares were sold as an unregistered offering under Section 4(a)(2) and Rule 506 of Regulation D to accredited investors, with no registration rights granted and no general solicitation used.
Bluejay Diagnostics, Inc. outlined its response to investor NorthStrive Fund II LP, which suggested that Bluejay explore acquiring a Phase‑1‑ready therapeutic program targeting refractory chronic cough to expand its pipeline.
Bluejay emphasized that its current priority is advancing its Symphony™ near‑patient critical care diagnostics platform, including completing the SYMON™ II clinical study, scaling up manufacturing, and preparing an FDA submission. The board and management, with external clinical and regulatory advisors, plan to carefully evaluate the proposed acquisition for strategic fit, potential synergies with Symphony™, and impact on existing shareholders, while remaining focused on prudent use of cash and fiduciary obligations.
Bluejay Diagnostics, Inc. filed a current report describing new clinical visibility for its Symphony IL-6 Test. An abstract based on the multicenter SYMON-I pilot study was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting in Atlanta.
The presentation will cover how interleukin-6 levels measured in the emergency department relate to organ dysfunction, assessed by Sequential Organ Failure Assessment scores over the first three days of hospitalization in sepsis patients. Bluejay also highlights its ongoing SYMON-II validation study, intended to further evaluate IL-6 as a prognostic biomarker linked to mortality and other clinically meaningful outcomes in critically ill patients.
Bluejay Diagnostics, Inc. filed a current report after issuing a press release that outlines its 2026 strategic outlook and recent progress. The company continues advancing its Symphony platform and SYMON II clinical study for an Interleukin-6 test to support sepsis risk assessment, with enrollment and site activity proceeding as planned for regulatory purposes.
Bluejay reports ongoing manufacturing scale-up, supply-chain work, and process validation to prepare for potential commercialization. During February 2026, previously issued prefunded warrants were fully exercised and converted into common shares, leaving approximately 972,000 common shares outstanding plus cash-exercisable warrants with strike prices above current trading levels.
The company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, after a $3.8 million warrant-inducement financing in April 2025 and a $4.5 million PIPE in October 2025. Net loss for 2025 was about $6.8 million. Management states that 2026 priorities center on clinical validation, manufacturing readiness, and positioning the Symphony platform for future regulatory submission and commercialization.
Bluejay Diagnostics, Inc. reported that all prefunded warrants issued in its October 2025 private placement were fully exercised as of February 19, 2026, leaving no prefunded warrants outstanding. After these exercises, the company has approximately 972,000 shares of common stock outstanding.
The company also has cash exercisable warrants outstanding for approximately 1.5 million shares, all with a cash exercise price of $7.00 or higher per share. Bluejay highlighted that several recent Schedule 13G filings do not reflect its 1-for-4 reverse stock split completed on January 29, 2026, so share amounts in those reports may appear higher than current post-split ownership.
Bluejay Diagnostics filed a current report describing clinical and operational progress for its Symphony System and IL-6 sepsis test. The company has enrolled 545 patients in its multicenter SYMON™ II IL-6 monitoring study, toward a stated target of 750 patients, which management says exceeds initial expectations and reduces enrollment execution risk. All patients have been enrolled under approved IRB protocols, and management believes the growing, diverse dataset will support future regulatory and partner discussions.
Bluejay also highlights continued advancement of manufacturing readiness across antibodies, tooling, analytical validation, and commercial manufacturing infrastructure, with technology transfer designed to avoid single points of failure. The company reiterates that its Symphony System does not yet have FDA regulatory clearance and cannot be marketed as a diagnostic product in the United States until authorization is obtained.
Bluejay Diagnostics, Inc. implemented a 1-for-4 reverse stock split of its common stock, effective January 29, 2026. Every four pre-split shares were converted into one share, reducing issued and outstanding common shares from 2,834,133 to approximately 708,533.
The number of shares issuable upon exercise of prefunded warrants was reduced from 1,055,000 to 263,750, and all equity awards, warrants, and shares reserved under equity plans were adjusted proportionately. The par value, voting rights, and other terms of the common stock were unchanged.
No fractional shares are being issued; eligible stockholders will receive cash in lieu of fractions, based on a recent average closing price. Trading continues on the Nasdaq Capital Market under the symbol “BJDX” with a new CUSIP number, and the company’s transfer agent is handling the share exchange and book-entry adjustments.
Bluejay Diagnostics (BJDX) furnished an Item 7.01 Regulation FD Disclosure on Form 8-K. The company issued a press release providing a 2025 third quarter financial and corporate update, furnished as Exhibit 99.1.
The information in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and is not incorporated by reference unless specifically identified. This update follows the company’s Form 10-Q for the quarter ended September 30, 2025, filed on November 7, 2025.
Bluejay Diagnostics entered into a private placement that closed on October 10, 2025, selling 175,000 shares of common stock and pre-funded warrants for up to 2,075,000 shares, together with Series F warrants for up to 4,500,000 shares. The combined price was $2.00 per share (or pre-funded warrant) plus accompanying Series F warrants to acquire two shares. The company received approximately $4.0 million in proceeds after fees.
Pre-funded warrants are immediately exercisable at $0.0001 per share and expire once exercised. Series F warrants are immediately exercisable at $1.75 per share and expire five and one-half years from issuance. The placement agent received warrants to purchase up to 180,000 shares, with an exercise price equal to 125% of the combined price per share and Series F warrants sold.
Bluejay agreed to register for resale the 175,000 shares and 6,755,000 warrant shares, file by October 24, 2025, and keep the registration effective until the registered shares may be sold under Rule 144. Issuances are restricted for 90 days after effectiveness, and certain variable-rate deals and splits are limited for one year. Warrant exercises are capped at 4.99% or 9.99% beneficial ownership, subject to notice-based adjustments.
Bluejay Diagnostics, Inc. entered into an amendment on October 3, 2025 to its existing Master Service Agreement and Master Supply Agreement with Sanyoseiko Co., Ltd.. The change is tied to Bluejay’s commercialization of its Symphony platform, a near-patient testing system designed to provide rapid results for biomarkers such as IL-6 used in sepsis management.
Under the amended arrangements, Sanyoseiko will provide end-to-end support for the Symphony platform. This includes supporting redevelopment of analyzers and cartridges with hardware, software, and design updates, managing raw material sourcing and vendor compliance, and acting as Bluejay’s contract manufacturer for analyzers, cartridges, and related components. Sanyoseiko will also handle fulfillment, kit assembly, labeling, packaging, shipping, and quality control, as well as regulatory and quality management support and equipment storage and maintenance. Bluejay also furnished a related press release as an exhibit.
Bluejay Diagnostics, Inc. reported that its Board of Directors updated leadership roles on the Board and its key committees, effective August 15, 2025. Donald R. Chase was appointed Chairperson of the Board, succeeding Douglas C. Wurth. Mr. Wurth became Chairperson of the Nominating and Corporate Governance Committee, succeeding Fred S. Zeidman, and Mr. Zeidman was named Chairperson of the Compensation Committee, succeeding Mr. Chase.
Mr. Chase continues to serve as Chairperson of the Audit Committee, and all three standing Board committees remain composed of Messrs. Chase, Wurth, and Zeidman. The Board describes these changes as part of its periodic review of governance assignments and notes that all three directors are considered independent under Nasdaq listing rules and Rule 10A-3 under the Securities Exchange Act of 1934.
Bluejay Diagnostics, Inc. furnished a Current Report stating that, following its quarterly report for the fiscal quarter ended June 30, 2025, the company issued a press release providing a 2025 second quarter business and corporate update.
The press release is furnished as Exhibit 99.1 and the cover page interactive data file is included as Exhibit 104. The filing specifies the information is being furnished and is not "filed" under the Exchange Act and will not be incorporated by reference into other filings unless identified. The report was signed by Neil Dey, President and Chief Executive Officer.